Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

This valuation suggests that the market may be underestimating Biogen's potential, particularly if the company can achieve sales inflections or positive pipeline developments. Biogen's product ...

Furthermore, Biogen’s efforts in pipeline diversification, particularly in immunology and inflammatory treatments, bolster its future growth potential. The recent positive data update from the ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

This valuation suggests that the market may be underestimating Biogen's potential, particularly if the company can achieve sales inflections or positive pipeline developments. Biogen's product ...

Biogen Inc. (NASDAQ:BIIB), a leading biotechnology company specializing in neurological treatments, finds itself at a critical juncture as it navigates the launch of its highly anticipated Alzheimer's ...

We also think the market underestimates Biogen's pipeline, which includes a continuing partnership with Ionis (including tau-targeting Alzheimer's drug BIIB080) and drug candidates to treat ...

Some of these savings will be put back into Biogen’s product launches and pipeline. Biogen’s cost-cutting measures have included layoffs. Back in July 2023, Biogen said it would cut another ...

Biogen also reported progress in its development pipeline with significant clinical milestones and regulatory advancements. Biogen’s improved cost structure and strategic initiatives ...